Abstract
ObjectiveTo report a case of gross haematuria in a patient on leflunomide. In 1998, the USA Food and Drug Administration approved leflunomide for the treatment of active rheumatoid arthritis. Leflunomide is classified as a disease-modifying anti-rheumatic drug (DMARD), which has immunomodulatory, anti-inflammatory, analgesics, and antipyretic effects.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
